Literature DB >> 11173913

Transcription factor-targeted therapies in inflammatory bowel disease.

K Mitsuyama1, A Suzuki, N Tomiyasu, K Takaki, A Toyonaga, M Sata.   

Abstract

Although the causes of inflammatory bowel disease currently are not fully understood, increasing evidence implicates cytokines as key factors in the development of this disorder. The rationale for cytokine-targeted therapy for inflammatory bowel disease has been refined significantly, and clinical studies have been initiated. Recent investigations have focused on transcription factors that regulate production and activation of cytokines, including the nuclear factor-kappa B, the p38 mitogen-activated protein kinase, the peroxisome proliferator-activated receptor-gamma, and the Janus kinases/signal transducers and activator of transcription pathways. Although their exact role in inflammatory bowel disease is still unknown, further studies may lead to identification of additional possible targets for therapeutic intervention that could improve management of the disease. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11173913     DOI: 10.1159/000051914

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

1.  STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice.

Authors:  K Mitsuyama; S Matsumoto; S Rose-John; A Suzuki; T Hara; N Tomiyasu; K Handa; O Tsuruta; H Funabashi; J Scheller; A Toyonaga; M Sata
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

Review 2.  Pro-inflammatory effects of silver nanoparticles in the intestine.

Authors:  Adelaide Sousa; Tracey D Bradshaw; Daniela Ribeiro; Eduarda Fernandes; Marisa Freitas
Journal:  Arch Toxicol       Date:  2022-03-16       Impact factor: 6.168

3.  Circulating levels of cyclosporin A in inflammatory bowel disease: relationships with lymphocyte inhibition and the age of patients.

Authors:  Giulia Angeloni; Miriam Latteri; Raffaele Manna; Carlo Rumi; Giovanni Gasbarrini; Pierluigi Navarra
Journal:  Eur J Clin Pharmacol       Date:  2004-03-26       Impact factor: 2.953

Review 4.  Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models.

Authors:  Sun Young Moon; Kwang Dong Kim; Jiyun Yoo; Jeong-Hyung Lee; Cheol Hwangbo
Journal:  Molecules       Date:  2021-05-10       Impact factor: 4.411

5.  FoxO1 regulates TLR4/MyD88/MD2-NF-κB inflammatory signalling in mucosal barrier injury of inflammatory bowel disease.

Authors:  Chenyang Han; Li Guo; Yongjia Sheng; Yi Yang; Jin Wang; Yanling Gu; Wenyan Li; Xiaohong Zhou; Qingcai Jiao
Journal:  J Cell Mol Med       Date:  2020-02-14       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.